memantine has been researched along with Amyotrophic Lateral Sclerosis in 9 studies
Amyotrophic Lateral Sclerosis: A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Memantine treatment significantly delayed the disease progression and increased the life span of SOD1(G93A) mice, from 121." | 5.33 | Memantine prolongs survival in an amyotrophic lateral sclerosis mouse model. ( Wang, R; Zhang, D, 2005) |
| "Memantine treatment significantly delayed the disease progression and increased the life span of SOD1(G93A) mice, from 121." | 1.33 | Memantine prolongs survival in an amyotrophic lateral sclerosis mouse model. ( Wang, R; Zhang, D, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 4 (44.44) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, A | 1 |
| Liu, C | 1 |
| Ye, W | 2 |
| Huang, D | 1 |
| She, W | 1 |
| Liu, X | 1 |
| Fung, CP | 1 |
| Xu, N | 1 |
| Suen, MC | 1 |
| Sung, HHY | 1 |
| Williams, ID | 1 |
| Zhu, G | 1 |
| Qian, PY | 1 |
| Radulović, S | 1 |
| Sunkara, S | 1 |
| Maurer, C | 1 |
| Leitinger, G | 1 |
| Wong, C | 1 |
| Dakin, RS | 1 |
| Williamson, J | 1 |
| Newton, J | 1 |
| Steven, M | 1 |
| Colville, S | 1 |
| Stavrou, M | 1 |
| Gregory, JM | 1 |
| Elliott, E | 1 |
| Mehta, AR | 1 |
| Chataway, J | 1 |
| Swingler, RJ | 1 |
| Parker, RA | 1 |
| Weir, CJ | 1 |
| Stallard, N | 1 |
| Parmar, MKB | 1 |
| Macleod, MR | 1 |
| Pal, S | 1 |
| Chandran, S | 1 |
| You, FL | 1 |
| Xia, GF | 1 |
| Cai, J | 1 |
| Yáñez, M | 1 |
| Matías-Guiu, J | 1 |
| Arranz-Tagarro, JA | 1 |
| Galán, L | 1 |
| Viña, D | 1 |
| Gómez-Pinedo, U | 1 |
| Vela, A | 1 |
| Guerrero, A | 1 |
| Martínez-Vila, E | 1 |
| García, AG | 1 |
| Blasco, H | 1 |
| Patin, F | 1 |
| Andres, CR | 1 |
| Corcia, P | 1 |
| Gordon, PH | 1 |
| de Carvalho, M | 1 |
| Pinto, S | 1 |
| Costa, J | 1 |
| Evangelista, T | 1 |
| Ohana, B | 1 |
| Pinto, A | 1 |
| Levine, TD | 1 |
| Bowser, R | 1 |
| Hank, N | 1 |
| Saperstein, D | 1 |
| Wang, R | 1 |
| Zhang, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial[NCT04302870] | Phase 2/Phase 3 | 800 participants (Anticipated) | Interventional | 2020-02-27 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for memantine and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Digging Deeper: Advancements in Visualization of Inhibitory Synapses in Neurodegenerative Disorders.
Topics: Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Brain; Humans; Huntington Disease; Levodo | 2021 |
Amyotrophic Lateral Sclerosis, 2016: existing therapies and the ongoing search for neuroprotection.
Topics: Amyotrophic Lateral Sclerosis; Biomarkers; Clinical Trials as Topic; Frontotemporal Dementia; Humans | 2016 |
3 trials available for memantine and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Motor Neuron Disease Systematic Multi-Arm Adaptive Randomised Trial (MND-SMART): a multi-arm, multi-stage, adaptive, platform, phase III randomised, double-blind, placebo-controlled trial of repurposed drugs in motor neuron disease.
Topics: Amyotrophic Lateral Sclerosis; Double-Blind Method; Humans; Memantine; Motor Neuron Disease; Neurode | 2022 |
A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis.
Topics: Adolescent; Adult; Aged; Amyotrophic Lateral Sclerosis; Double-Blind Method; Excitatory Amino Acid A | 2010 |
A pilot trial of memantine and riluzole in ALS: correlation to CSF biomarkers.
Topics: Amyotrophic Lateral Sclerosis; Animals; Biomarkers; Disease Progression; Excitatory Amino Acid Antag | 2010 |
4 other studies available for memantine and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Selective
Topics: Amyotrophic Lateral Sclerosis; Animals; Biological Products; C9orf72 Protein; DNA; Drosophila; Front | 2022 |
Behavioural Variant Frontotemporal Dementia due to
Topics: Aged; Amyotrophic Lateral Sclerosis; Cyclins; Frontotemporal Dementia; Humans; Male; Memantine; Muta | 2023 |
The neuroprotection exerted by memantine, minocycline and lithium, against neurotoxicity of CSF from patients with amyotrophic lateral sclerosis, is antagonized by riluzole.
Topics: Amyotrophic Lateral Sclerosis; Animals; Cell Survival; Excitatory Amino Acid Antagonists; Humans; Li | 2014 |
Memantine prolongs survival in an amyotrophic lateral sclerosis mouse model.
Topics: Amyotrophic Lateral Sclerosis; Animals; Disease Models, Animal; Excitatory Amino Acid Antagonists; G | 2005 |